Hydromorphone Quintian 10 Mg/Ml

Hydromorphone, the active ingredient in Hydromorphone Quintian 10 Mg/mL, is an opioid analgesic presented as a 10 mg/mL sterile injection for intravenous administration. It is indicated for the management of severe, acute and postoperative pain in adult patients when a strong opioid is required.

GNH USA supplies Hydromorphone Quintian 10 Mg/mL as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets EU quality standards and is distributed under strict regulatory compliance.

Hydromorphone is an opioid analgesic used to manage pain that involves the central nervous system.

- Severe pain: provides potent analgesia for severe pain unresponsive to non‑opioid agents. - Acute pain: relieves acute pain episodes such as injury or trauma. - Postoperative pain: controls pain following surgical procedures.

Hydromorphone may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea - Constipation - Drowsiness - Dizziness

Serious or Rare Side Effects: - Respiratory depression - Severe hypotension - Anaphylactic or severe allergic reaction - Dependence, tolerance, or addiction

Before initiating therapy, clinicians should consider several safety measures.

- Assess respiratory function: monitor breathing before and during treatment. - Evaluate renal and hepatic function: adjust use if impairment is present. - Avoid in patients with known hypersensitivity to hydromorphone or its excipients. - Use caution in elderly patients: increased sensitivity to central nervous system effects. - Concomitant CNS depressants: heightened risk of sedation and respiratory depression. - Store at controlled room temperature: keep in original container, protect from light and moisture.

Hydromorphone can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Other opioids: additive respiratory depression. - Central nervous system depressants (e.g., benzodiazepines, barbiturates): increased sedation. - Monoamine oxidase inhibitors (MAOIs): risk of severe adverse reactions.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): may raise hydromorphone levels. - Serotonergic agents (e.g., SSRIs, tramadol): potential for serotonin syndrome.